Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT06608472

PHASE3

Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension

Sponsor: Eurofarma Laboratorios S.A.

View on ClinicalTrials.gov

Summary

This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on systolic blood pressure (SBP) in the sitting position in the medical office in patients with SAH after 8 weeks of treatment.

Official title: A Phase III, Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, Efficacy and Safety Study of a New Fixed-dose Combination of an Angiotensin Receptor Blocker and a Thiazide Diuretic for the Treatment of Essential (primary) Arterial Hypertension

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

292

Start Date

2026-11-30

Completion Date

2029-10-30

Last Updated

2024-11-27

Healthy Volunteers

Conditions

Essential Arterial Hypertension

Interventions

DRUG

N0877

1 tablet of N0877 and 1 tablet of Placebo of Benicar HCT®

DRUG

Benicar HCT ® Tablets 40 mg/25 mg

1 tablet of Benicar HCT® and 1 tablet of Placebo of N0877

Inclusion Criteria: 1. Ability to confirm voluntary participation and agree to all purposes of the study, signing and dating the Informed Consent Form in two copies. 2. Age ≥ 18 years. 3. Medical office blood pressure with SBP ≥ 160 mm Hg or DBP ≥ 100 mm Hg without pharmacological treatment or which is not adequately controlled with monotherapy or with a combination of two drugs in which at least one of the drugs is not at the maximum dose. 4. Uncontrolled arterial hypertension (medical office BP with SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg) after at least two (02) weeks of run-in treatment. 5. Compliance with run-in treatment ≥ 80% and ≤ 120%. Exclusion Criteria: 1. Pregnant or lactating women. 2. Women in the reproductive age or of childbearing potential who do not agree to use a proven effective contraceptive method, unless they are surgically sterile or expressly declare themselves to be free from the risk of pregnancy because they do not engage in sexual practices or engage in them in a non-reproductive manner. 3. Medical office blood pressure with SBP ≥ 180 mm Hg or DBP ≥ 110 mm mmHg. 4. Resistant hypertension or secondary hypertension of any etiology (including renovascular disease, pheochromocytoma and Cushing\'s syndrome). 5. Concomitant presence of Coronary Artery Disease, Congestive Heart Failure, Liver Failure and/or Chronic Kidney Disease stage IV or V. 6. History of hypertensive emergencies in the last 6 months. 7. Moderate to severe cardiovascular (acute myocardial infarction or unstable angina, unstable or life-threatening arrhythmia) and/or cerebrovascular events within the last 6 months or any other disorder that in the opinion of the investigator excludes the participant from the study. 8. Participant who is unwilling to switch from hypertension treatment to study medications. 9. 12-lead electrocardiogram (ECG) with any clinically significant abnormality. 10. Drug or alcohol abuse in the last 2 years. 11. Allergic or hypersensitivity reactions to angiotensin II receptor blockers, thiazide diuretics or medication excipients.

Locations (1)

Eurofarma Laboratórios S.A

Itapevi, São Paulo, Brazil